Nestlé S.A. (NESN.SW)
| Chiusura precedente | 88,82 |
| Aperto | 86,80 |
| Denaro | 0,00 x 0 |
| Domanda | 0,00 x 0 |
| Min-Max giorno | 85,70 - 88,14 |
| Intervallo di 52 settimane | 85,70 - 108,24 |
| Volume | |
| Media Volume | 3.705.535 |
| Capitalizzazione | 226,07B |
| Beta (mensile su 5 anni) | 0,32 |
| Rapporto PE (ttm) | 20,59 |
| EPS (ttm) | 4,27 |
| Prossima data utili | 25 lug 2024 |
| Rendimento e dividendo (futuro) | 3,00 (3,38%) |
| Data ex dividendo | 22 apr 2024 |
| Stima target 1A | 106,30 |
GlobeNewswireChanges in the Executive Board of Nestlé S.A.
[Ad hoc announcement pursuant to Art. 53 LR] This press release is also available in Français (pdf) and Deutsch (pdf) ............. Changes in the Executive Board of Nestlé S.A. Vevey, September 22, 2023 After nine years as Chief Executive Officer of Nestlé Health Science, Greg Behar will leave Nestlé as of December 31, 2023, to pursue new professional interests outside the company. Greg Behar helped establish Nestlé Health Science as a leader in nutritional health solutions, growing the company
- GlobeNewswire
Nestlé divests its Palforzia business
[Ad hoc announcement pursuant to Art. 53 LR] This press release is also available in Français (pdf) and Deutsch (pdf) ............. Vevey, September 4, 2023 Nestlé divests its Palforzia business Nestlé announced today that is has divested Palforzia, its peanut allergy treatment business, to Stallergenes Greer, a biopharmaceutical company which specializes in the diagnosis and treatment of allergies. The transaction was closed upon signing. This agreement follows Nestlé's announcement last year t
